Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin vs placebo as post‑ASCT consolidation in high‑risk Hodgkin lymphoma
2009-016947-20Phase 3Completed
- Sponsor
- Seagen Inc.
- Start
- Feb 2010
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Hodgkin lymphoma (HL) comparing Brentuximab vedotin + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Progression-free survival (per independent review facility). Started Feb 2010; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2009-016947-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016947-20.